Research presented at the European Society of Cardiology conference indicates that cholesterol-reducing medications known as statins may substantially lower dementia risk. The study followed 132,585 individuals in Denmark between 2006 and 2021, with participants who initiated statin treatment showing a 10% reduction in dementia risk overall. Those who began taking statins earlier experienced a 15% lower relative risk of developing dementia over a 10-year period, while late initiation was associated with a 10% reduction.
Among the study population, 2.7% ultimately developed dementia. The research was conducted exclusively among individuals with type 2 diabetes and was published in the Lancet Regional Health Europe journal. Researchers theorize that statins may protect brain health by reducing low-density lipoprotein cholesterol, which can harden or narrow blood vessels supplying the brain, thereby improving cerebral blood flow and reducing dementia risk.
Experts noted that statins are widely available and inexpensive medications already among the most commonly prescribed drugs globally. Dr. Tummas Ternhamar from Copenhagen University Hospital, who presented the findings, suggested the results support a multi-factor approach to dementia prevention that includes cholesterol management alongside other interventions such as physical activity and proper nutrition. He emphasized that timing appears significant, with earlier intervention showing better outcomes than delayed treatment.
The Lancet dementia commission previously identified 14 modifiable risk factors that, if addressed throughout life, could prevent or delay approximately 45% of dementia cases. High cholesterol detection and treatment beginning in midlife was highlighted as one such factor. Independent experts emphasized that while the study demonstrates an association between statin use and reduced dementia risk, additional research is necessary to establish direct causation and to further clarify the mechanisms underlying this potential protective effect.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI